Lilly Reports Second-Quarter 2016 Results, Provides Financial Expectations Through the Remainder of the Decade (NYSE:LLY)

Lilly Reports Second-Quarter 2016 Results, Provides Financial Expectations Through the Remainder of the Decade (NYSE:LLY)

Lilly Convenes Leaders at National Mayor's Conference to Address Impact of Alzheimer's Disease on Local Communities (NYSE:LLY)

Regional Community Conversations Events to Spark Creation of Preparedness Plans across the Nation

Lilly Convenes Leaders at National Mayor's Conference to Address Impact of Alzheimer's Disease on Local Communities (NYSE:LLY)

Diabetes Scholars Foundation Announces 2016 Scholarship Recipients (NYSE:LLY)

For fifth year in a row, Lilly Diabetes helps send standout students to college

Diabetes Scholars Foundation Announces 2016 Scholarship Recipients (NYSE:LLY)

Lilly Declares Third-Quarter 2016 Dividend (NYSE:LLY)

Lilly Declares Third-Quarter 2016 Dividend (NYSE:LLY)

German Supreme Court Grants Lilly Appeal in Alimta® Vitamin Regimen Patent Lawsuit (NYSE:LLY)

Alimta Case Returned to Court of Appeal for New Ruling

German Supreme Court Grants Lilly Appeal in Alimta® Vitamin Regimen Patent Lawsuit (NYSE:LLY)

Jardiance® (empagliflozin) significantly reduced the risk of progressive kidney disease in adults with type 2 diabetes with established cardiovascular disease (NYSE:LLY)

Jardiance® (empagliflozin) significantly reduced the risk of progressive kidney disease in adults with type 2 diabetes with established cardiovascular disease (NYSE:LLY)

Aarti Shah named chief information officer (NYSE:LLY)

Aarti Shah named chief information officer (NYSE:LLY)

New Data Show Lilly's Once-Weekly Trulicity® (dulaglutide) in Combination with Insulin Glargine Improves Glycemic Control in People with Type 2 Diabetes (NYSE:LLY)

New Data Show Lilly's Once-Weekly Trulicity® (dulaglutide) in Combination with Insulin Glargine Improves Glycemic Control in People with Type 2 Diabetes (NYSE:LLY)

New Jardiance® (empagliflozin) data show that reduced risk for cardiovascular (CV) death was consistent across age groups in adults with type 2 diabetes (NYSE:LLY)

New Jardiance® (empagliflozin) data show that reduced risk for cardiovascular (CV) death was consistent across age groups in adults with type 2 diabetes (NYSE:LLY)

New study results show Tradjenta® (linagliptin) reduces blood sugar in adults with type 2 diabetes at risk for kidney impairment (NYSE:LLY)

New study results show Tradjenta® (linagliptin) reduces blood sugar in adults with type 2 diabetes at risk for kidney impairment (NYSE:LLY)

New Study Findings Underscore Importance of Physician/Patient Communication on Insulin Adherence and Outcomes (NYSE:LLY)

New Study Findings Underscore Importance of Physician/Patient Communication on Insulin Adherence and Outcomes (NYSE:LLY)

Data in The Lancet Show Olaratumab Plus Doxorubicin Offered 11.8-Month Increase in Overall Survival in Patients with Advanced Soft Tissue Sarcoma, as Reported by Lilly and Memorial Sloan Kettering Researchers (NYSE:LLY)

Data in The Lancet Show Olaratumab Plus Doxorubicin Offered 11.8-Month Increase in Overall Survival in Patients with Advanced Soft Tissue Sarcoma, as Reported by Lilly and Memorial Sloan Kettering Researchers (NYSE:LLY)

Lilly and American Migraine Foundation Announce $1 Million Grant for Launch of First Patient Registry to Advance Research and Development in Migraine (NYSE:LLY)

Lilly and American Migraine Foundation Announce $1 Million Grant for Launch of First Patient Registry to Advance Research and Development in Migraine (NYSE:LLY)

Patient-reported outcomes across phase 3 studies of baricitinib demonstrate statistically significant improvements in physical function and quality of life symptoms in patients with rheumatoid arthritis (RA) (NYSE:LLY)

Pivotal trials show treatment with baricitinib resulted in significant improvements in pain, fatigue and ability to perform daily activities compared to methotrexate - the current standard of care - and adalimumab (Humira^®)*



Patient-reported outcomes across phase 3 studies of baricitinib demonstrate statistically significant improvements in physical function and quality of life symptoms in patients with rheumatoid arthritis (RA) (NYSE:LLY)

Baricitinib significantly reduces joint damage progression in rheumatoid arthritis in patients who do not respond to conventional DMARDs (NYSE:LLY)

Patients from pivotal 24-week phase 3 trial RA-BUILD who entered long-term extension study, RA-BEYOND, demonstrate baricitinib continues to inhibit radiographic progression of structural joint damage over one year

Baricitinib significantly reduces joint damage progression in rheumatoid arthritis in patients who do not respond to conventional DMARDs (NYSE:LLY)

Studies Demonstrate Lilly's Taltz® (ixekizumab) Maintained or Achieved High Levels of Skin Clearance for Patients with Moderate-to-Severe Plaque Psoriasis through 60 Weeks: Results Published in the New England Journal of Medicine (NYSE:LLY)

INDIANAPOLIS, June 8, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the New England Journal of Medicine has published detailed results from three pivotal Phase 3 studies—UNCOVER-1, UNCOVER-2 and UNCOVER-3—that demonstrated the efficacy and safety of Taltz^® (ixekizumab) through 60 weeks in patients with moderate-to-severe plaque psoriasis. This publication also detailed 12-week efficacy data for patients treated with Taltz in UNCOVER-1.



Studies Demonstrate Lilly's Taltz® (ixekizumab) Maintained or Achieved High Levels of Skin Clearance for Patients with Moderate-to-Severe Plaque Psoriasis through 60 Weeks: Results Published in the New England Journal of Medicine (NYSE:LLY)

Results of Clinical and Patient-Reported Outcomes Data for Baricitinib in Patients with Rheumatoid Arthritis to be Presented at Annual European Congress of Rheumatology (EULAR 2016) (NYSE:LLY)

Lilly immunology portfolio to be featured in 16 presentations



Results of Clinical and Patient-Reported Outcomes Data for Baricitinib in Patients with Rheumatoid Arthritis to be Presented at Annual European Congress of Rheumatology (EULAR 2016) (NYSE:LLY)

Early-Phase Immuno-Oncology Studies of Lilly's ALIMTA® (pemetrexed) and CYRAMZA® (ramucirumab) with Merck's KEYTRUDA® (pembrolizumab) Show Encouraging Results in Non-Small Cell Lung Cancer (NYSE:LLY)

Patients Receiving ALIMTA-KEYTRUDA-Carboplatin Combination Demonstrate Response Rate of 71 Percent
Majority of NSCLC Patients Receiving CYRAMZA-KEYTRUDA Combination Experience Decrease in Target Lesions
Responses Observed Regardless of PD-L1 Expression

Early-Phase Immuno-Oncology Studies of Lilly's ALIMTA® (pemetrexed) and CYRAMZA® (ramucirumab) with Merck's KEYTRUDA® (pembrolizumab) Show Encouraging Results in Non-Small Cell Lung Cancer (NYSE:LLY)

Lilly Announces Results from MONARCH 1 Trial of Abemaciclib Monotherapy (NYSE:LLY)

Phase 2 Data Confirms Single-Agent Activity of Abemaciclib Dosed on a Continuous Schedule in HR+, HER2- Metastatic Breast Cancer Patients

Lilly Announces Results from MONARCH 1 Trial of Abemaciclib Monotherapy (NYSE:LLY)

Lilly Announces Diabetes Commercial Update Investor Call (NYSE:LLY)

Lilly Announces Diabetes Commercial Update Investor Call (NYSE:LLY)